Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations

Journal of Medical Investigation

Volumn 57, Issue 3-4, 2010, Pages 245-250

  Takahashi, Masaaki ^a,b   Hirano, Atsushi ^a,b   Okubo, Nami ^a   Kinoshita, Eri ^a   Nomura, Toshiharu ^a   Kaneda, Tsuguhiro ^a  

^a KINJO GAKUIN UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

CCR5 antagonist; HIV 1; LC MS; Maraviroc; Therapeutic drug monitoring

Indexed keywords

DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; RITONAVIR; TIPRANAVIR;

ACCURACY; ADULT; ARTICLE; CALIBRATION; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PROCESS DEVELOPMENT; PRODUCT RECOVERY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649648361     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.57.245     Document Type: Article

References (19)

1. de Bethune MP, Hertogs K: Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr Med Res Opin 22: 2603-2612, 2006
2. Machouf N, Thomas R, Nguyen VK, Trottier B, Boulassel MR, Wainberg MA, Routy JP: Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 78: 608-613, 2006
3. Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A: Drug - class - wide resistance to antiretrovirals in HIV-infected patients failing therapy: preva lence, risk factors and virological outcome. An-tivir Ther 11: 553-560, 2006
4. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA: The prevalence of antiretroviral drug resistance in the United States. AIDS 18: 1393-1401, 2004
5. De Clercq E: Emerging anti-HIV drugs. Expert Opin Emerg Drugs 10: 241-273, 2005
6. Gulick RM: New antiretroviral drugs. Clin Mi-crobiol Infect 9: 186-193, 2003
7. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M: Ma-raviroc (UK-427,857), a potent, orally bioavail- able, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721- 4732, 2005
8. Carter NJ, Keating GM: Maraviroc. Drugs 67: 2277-2290, 2007
9. Vandekerckhove L, Verhofstede C, Vogelaers D: Maraviroc: integration of a new antiretrovi-ral drug class into clinical practice. J Antimi-crob Chemother 61: 1187-1190, 2008
10. MacArthur RD, Novak RM: Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47: 236-241, 2008
11. Lorenzen T, Stoehr A, Walther I, Plettenberg A: CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV - 1. Eur J Med Res 12: 419-425, 2007
12. Bredeek UF, Harbour MJ: CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. Eur J Med Res 12: 427-434, 2007
13. Product information, SELZENTRY (maraviroc tablet), Pfizer, New York, NY, USA: http://www.pfizer.com/products/rx/rx_product_selzentry.jsp
14. Hyland R, Dickins M, Collins C, Jones H, Jones B: Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 66: 498-507, 2008
15. Fayet A, Beguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, Cavassini M, Gunthard HF, Buclin T, Biollaz J, Rochat B, Decosterd LA: A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravi-rine. J Chromatogr B Analyt Technol Biomed Life Sci 877: 1057-1069, 2009
16. Martin J, Deslandes G, Dailly E, Renaud C, Reliquet V, Raffi F, Jolliet P: A liquid chroma-tography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. J Chromatogr B Analyt Technol Biomed Life Sci 877: 3072-3082, 2009
17. Notari S, Tommasi C, Nicastri E, Bellagamba R, Tempestilli M, Pucillo LP, Narciso P, Ascenzi P: Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. IUBMB Life 61: 470-475, 2009
18. The Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS), published at http://AIDSinfo.nih.gov, 1 December 2009.
19. Hardy D, Reynes J, Konourina I, Wheeler D, Moreno S, van der Ryst E, Towner W, Horban A, Mayer H, Goodrich J: Paper presented at the 15th Conference on Retrovirus and Opportunistic Infections, Abstruct 792, Boston, MA, US, on February 3-6, 2008.